Pfizer

Pfizer Inc.
Type	Public
Traded as	NYSE: PFE; S&P 500 component
Industry	Pharmaceuticals; Biotechnology
Founded	1849, Brooklyn, New York
Founder	Charles Pfizer; Charles F. Erhart
Headquarters	New York City, United States
Key people	Albert Bourla (Chairman and chief executive officer)
Products	Prescription medicines and vaccines in oncology, immunology, cardiology, endocrinology, neurology and infectious disease
Revenue	Approximately US$62.6 billion (2025)
Employees	Approximately 81,000
Website	pfizer.com

Pfizer Inc. is an American multinational pharmaceutical and biotechnology company headquartered in New York City. It was the third largest pharmaceutical company in the world by revenue in 2025, at approximately US$62.6 billion, behind Roche and Merck and Co.

The company was founded in 1849 in Brooklyn by the German immigrant cousins Charles Pfizer, a chemist, and Charles F. Erhart, a confectioner, as a fine chemicals business. It became, successively, a producer of citric acid by fermentation, the principal manufacturer of penicillin during the Second World War, a research-based pharmaceutical company from the 1950s, the developer of several of the best-selling medicines ever sold, and, in 2020 and 2021, the manufacturer with BioNTech of the first COVID-19 vaccine authorised in the West.

Its largest products by sales include Eliquis, an anticoagulant developed and marketed with Bristol Myers Squibb; Prevnar, a pneumococcal conjugate vaccine; Vyndaqel for transthyretin amyloid cardiomyopathy; Ibrance for breast cancer; Comirnaty, the COVID-19 vaccine; and Paxlovid, the oral antiviral.

Pfizer has also accumulated one of the largest records of legal penalties of any company in any industry. Its 2009 settlement of US$2.3 billion over the illegal promotion of Bextra remains among the largest healthcare fraud settlements in American history, and it followed earlier settlements over gabapentin and preceded further ones over Rapamune.

History

Chemicals and fermentation, 1849 to 1950

Charles Pfizer and his cousin Charles Erhart emigrated from Ludwigsburg in Württemberg and founded Charles Pfizer and Company in 1849 in Williamsburg, Brooklyn, with a loan of US$2,500 from Pfizer's father.

The first product was santonin, a treatment for intestinal worms, which Pfizer combined with a toffee flavouring devised by Erhart to make it palatable, and which sold well in a country where parasitic infection was common. The company added other fine chemicals including borax, camphor, cream of tartar and iodine, and grew substantially supplying painkillers, preservatives and disinfectants to the Union Army during the Civil War.

The transformation came with citric acid. Pfizer had imported it from Italian lemon and lime producers, a supply that was controlled by a cartel and interrupted by the First World War. The chemist James Currie and his assistant Jasper Kane developed a fermentation process using the mould Aspergillus niger fed on sugar, commercialised from 1919, which made Pfizer the world's largest citric acid producer and, more importantly, gave it expertise in deep-tank fermentation that no other company possessed at the scale.

That expertise determined the company's future. When the Allied governments sought to mass-produce penicillin after 1941, the problem was not the discovery, which was Alexander Fleming's, nor the purification, which was Florey and Chain's, but manufacture: surface culture in flasks produced quantities adequate for experiment and nothing more. Jasper Kane proposed applying deep-tank fermentation, the board approved the conversion of an ice plant in Brooklyn at considerable financial risk, and Pfizer produced the great majority of the penicillin used at the Normandy landings. The company emerged from the war with a manufacturing capability and a reputation it had not had in 1939.

Becoming a pharmaceutical company, 1950 to 1980

Penicillin became a commodity within a few years and Pfizer concluded that selling other companies' discoveries as a bulk manufacturer was not a business worth being in.

The decision to conduct its own research and to sell under its own name was taken under John McKeen and produced Terramycin, an antibiotic derived from soil samples collected worldwide, launched in 1950 with the company's own sales force. It was the first Pfizer product sold under a Pfizer label and it established the model the company has followed since.

International expansion followed quickly, with operations in dozens of countries by the 1960s, and diversification into agricultural chemicals, cosmetics and materials, most of which was later divested.

Research in this period produced Vibramycin, a doxycycline antibiotic, Feldene, an anti-inflammatory that became one of the first medicines to sell more than a billion dollars a year, and Diflucan and Zithromax in the following decade.

The blockbuster era, 1980 to 2000

Pfizer's central research operation at Sandwich in Kent, England, and at Groton, Connecticut, produced a sequence of medicines that made the company the largest in the industry.

Zoloft (sertraline), approved in 1991, became one of the most prescribed antidepressants. Norvasc (amlodipine) became a leading treatment for hypertension. Zithromax (azithromycin) became among the most prescribed antibiotics in the world.

Viagra (sildenafil) emerged from the Sandwich laboratory in circumstances that have become a standard illustration of serendipity in drug discovery. It was developed as a treatment for angina, acting on an enzyme in the pathway regulating blood vessel dilation. Trial results for angina were unremarkable and the trial participants reported an unexpected effect. Approved in March 1998, it became a cultural as well as a commercial phenomenon, the first oral treatment for erectile dysfunction, and it produced an enormous and largely unprepared market.

Lipitor (atorvastatin) was not discovered by Pfizer. It came from Warner-Lambert's Parke-Davis division and was the fifth statin to market, which under normal commercial reasoning would have made it a marginal product. Pfizer co-promoted it from 1996, concluded that its efficacy at lowering low-density lipoprotein cholesterol was materially better than its competitors', and in 2000 bought Warner-Lambert for approximately US$90 billion in a contested transaction after Warner-Lambert had agreed to merge with American Home Products.

Lipitor went on to generate more than US$125 billion of revenue over its patented life, more than any medicine in history, and the acquisition is generally regarded as among the best judgements made in the industry.

Consolidation, 2000 to 2019

The two decades after Warner-Lambert were dominated by very large acquisitions, by the expiry of the patents on the medicines that had made the company, and by a succession of legal settlements.

Pharmacia was acquired in 2003 for approximately US$60 billion, bringing Celebrex, Xalatan and Detrol, together with the animal health business that later became Zoetis. Wyeth followed in 2009 for approximately US$68 billion, bringing Prevnar, which has since become one of the company's largest products, along with Enbrel outside North America and a large biologics capability. King Pharmaceuticals came in 2010, Hospira, a generic injectables and biosimilars business, in 2015 for approximately US$17 billion, Medivation in 2016 for approximately US$14 billion, bringing the prostate cancer medicine Xtandi, Anacor in the same year, and Array BioPharma in 2019 for approximately US$11.4 billion.

Two attempted transactions failed publicly. A bid for AstraZeneca in 2014, at approximately US$118 billion, was rejected and was widely understood to be motivated partly by the opportunity to redomicile for tax purposes. A proposed merger with Allergan in 2015, valued at approximately US$160 billion and structured as an inversion moving Pfizer's domicile to Ireland, was abandoned in April 2016 after the United States Treasury issued rules specifically designed to prevent it.

The reverse direction was also pursued. Zoetis, the animal health business, was separated in 2013. The consumer health business was combined with GSK's in 2019 into a joint venture that was demerged as Haleon in 2022, and Pfizer sold its entire remaining Haleon stake in March 2025 for US$3.24 billion. Upjohn, holding the off-patent medicines including Lipitor and Viagra, was spun off in November 2020 and merged with Mylan to form Viatris.

The strategic logic of the divestments was to concentrate on innovative medicines, where margins and growth are highest and where scale in research matters, and to leave the categories in which a pharmaceutical company holds no advantage.

Albert Bourla, a Greek veterinarian who had joined Pfizer's animal health division in 1993, became chief executive in January 2019 and chairman in 2020.

COVID-19, 2020 to 2022

Pfizer's pandemic work is the most consequential thing the company has done and transformed its finances, its public profile and its politics.

In March 2020 Pfizer agreed to collaborate with BioNTech, a German company founded by Uğur Şahin and Özlem Türeci, which had been developing messenger RNA technology principally for cancer. The two had worked together on influenza vaccines since 2018. BioNTech supplied the platform and the candidate; Pfizer supplied development capability, regulatory experience and, above all, manufacturing at a scale BioNTech could not approach.

Bourla declined United States government development funding under Operation Warp Speed, taking an advance purchase agreement instead, on the stated reasoning that he wanted the company free of bureaucratic oversight and able to move at its own pace, and that the company should bear the financial risk. The decision was criticised as a claim to independence that obscured the extent of public investment in the underlying science, since the mRNA and lipid nanoparticle work rested on decades of government-funded research, including Katalin Karikó and Drew Weissman's nucleoside modification work at the University of Pennsylvania, for which they received the 2023 Nobel Prize.

Results were announced on 9 November 2020 showing efficacy above 90 per cent, a figure far higher than the 50 per cent threshold regulators had set and higher than most experts had expected. The United Kingdom granted emergency authorisation on 2 December 2020, the first Western country to do so, and the first dose outside a trial was given to Margaret Keenan in Coventry on 8 December. American emergency use authorisation followed on 11 December.

Manufacturing the vaccine was itself an achievement of an unusual kind. The process requires lipid nanoparticles produced in specialised equipment, and the product required storage at approximately minus 70 degrees Celsius, which necessitated a purpose-built distribution system including thermal shippers with dry ice and GPS tracking. Pfizer produced more than three billion doses in 2021 alone.

Comirnaty generated approximately US$37 billion in 2021 and Paxlovid, the oral antiviral protease inhibitor authorised in December 2021, a further large sum in 2022, taking Pfizer's revenue above US$100 billion, the first pharmaceutical company to reach that figure.

The subsequent contraction was severe. Demand for both products fell sharply in 2023 as the pandemic emergency ended and as governments worked through stockpiles, revenue fell by more than 40 per cent, Pfizer wrote off large quantities of Paxlovid returned by the United States government, and the share price fell to levels below where it had begun the pandemic. A cost reduction programme of several billion dollars followed.

2023 to 2026

Seagen was acquired in December 2023 for approximately US$43 billion, bringing antibody-drug conjugates, a modality that attaches a cytotoxic payload to an antibody targeting a tumour, and which is among the most productive areas in oncology. The purchase was the company's answer to the patent expiries approaching later in the decade and to the need to replace pandemic revenue.

Obesity has been the company's most conspicuous failure of the period. Pfizer pursued oral GLP-1 receptor agonists, which would compete with the injectable products from Novo Nordisk and Eli Lilly that have become the largest medicines in the world. Its first candidate was discontinued over tolerability, and danuglipron, advanced through 2024, was abandoned in April 2025 after a liver injury signal. The company then acquired Metsera in November 2025 in a transaction with a potential value exceeding US$10 billion, after a contested bidding process with Novo Nordisk that involved competition authorities and litigation, to acquire a position in the category.

In October 2025 Pfizer reached an agreement with the Trump administration to lower American drug prices voluntarily, in exchange for a three-year exemption from pharmaceutical-specific tariffs, conditional on further investment in domestic manufacturing. The company pledged US$70 billion of American investment. Several other large manufacturers reached comparable arrangements.

Other developments have included a partnership with Flagship Pioneering announced in July 2024 to co-develop ten candidates drawn from Flagship's portfolio of startups, with each party committing US$50 million upfront; the PfizerForAll consumer platform launched in August 2024; and several artificial intelligence collaborations, including an expanded agreement with Saama in February 2024 to apply machine learning across the research portfolio, work with the Abu Dhabi Department of Health on sickle cell disease, and participation in the Ignition AI Accelerator with NVIDIA in Singapore announced in October 2024.

Products

Principal medicines

Eliquis (apixaban), an oral anticoagulant developed and marketed jointly with Bristol Myers Squibb, generated approximately US$7.9 billion of Pfizer revenue in 2025, about 13 per cent of the total. It is used to prevent stroke in atrial fibrillation and to treat venous thromboembolism, and has largely displaced warfarin, which required frequent monitoring.

Prevnar is a pneumococcal conjugate vaccine protecting against invasive disease caused by Streptococcus pneumoniae. Successive versions covering more serotypes, from the original seven-valent through Prevnar 13 and Prevnar 20, have produced revenue of approximately US$6.5 billion in 2025 and have had a substantial measurable effect on childhood pneumonia and meningitis worldwide.

Vyndaqel and Vyndamax (tafamidis) treat transthyretin amyloid cardiomyopathy, a condition that had been regarded as rare and that improved diagnosis has shown to be considerably more common. They have grown rapidly and face competition from newer agents.

Ibrance (palbociclib) was the first CDK4/6 inhibitor approved for hormone receptor positive breast cancer and changed the treatment of that disease, though it has since lost share to competitors with stronger data in the adjuvant setting.

Xtandi (enzalutamide), from the Medivation acquisition and marketed with Astellas, treats prostate cancer; a phase 3 trial reported in October 2024 supported its combination with Talzenna in metastatic castration-resistant disease.

Comirnaty remains in use as an updated seasonal COVID-19 vaccine. Paxlovid (nirmatrelvir with ritonavir) remains the principal oral antiviral. Abrysvo is a respiratory syncytial virus vaccine approved in 2023 for older adults and for maternal immunisation to protect infants, with durable second-season efficacy reported in February 2024.

Xeljanz (tofacitinib) treats rheumatoid arthritis and other inflammatory conditions and has been constrained by safety labelling following a post-marketing trial showing increased cardiovascular and malignancy risk. Nurtec treats migraine. Padcev, from Seagen and partnered with Astellas, has changed the treatment of advanced bladder cancer.

Research

Pfizer conducts research principally at Groton and New London in Connecticut, Cambridge, Massachusetts, La Jolla, California, Pearl River, New York, and Sandwich in Kent, the last having been substantially reduced in 2011 in a decision widely criticised in Britain given the site's record.

The portfolio concentrates on oncology, which is the largest area and which the Seagen acquisition reinforced, immunology and inflammation, vaccines, internal medicine including cardiovascular and metabolic disease, and, since 2025, obesity.

Manufacturing is conducted at a large number of sites, with Kalamazoo in Michigan, Puurs in Belgium, where much of the European COVID-19 vaccine supply was produced, Rocky Mount in North Carolina, and Grange Castle in Ireland among the most significant. The Rocky Mount plant, which produces a substantial share of the injectable medicines used in American hospitals, was seriously damaged by a tornado in July 2023, producing national shortages and illustrating how concentrated the supply of basic hospital medicines has become.

Legal issues

Pfizer's record of penalties is among the largest of any corporation, and the pattern is consistent enough that it has been analysed as a business practice rather than a series of lapses.

Off-label promotion

American law permits doctors to prescribe an approved medicine for any purpose and prohibits the manufacturer from promoting uses the regulator has not approved, because approval is what establishes that the medicine works for that purpose.

Gabapentin (Neurontin), 2004. Warner-Lambert, acquired by Pfizer, had promoted the epilepsy drug for bipolar disorder, pain, migraine and attention deficit disorder without evidence. The case, brought by the whistleblower David Franklin, revealed the use of paid advisory boards, ghostwritten articles and continuing medical education as promotional instruments, and produced a settlement of US$430 million.

Bextra, 2009. Pfizer pleaded guilty to a felony violation of the Food, Drug and Cosmetic Act for promoting the anti-inflammatory Bextra at doses and for conditions the Food and Drug Administration had specifically declined to approve, having rejected the application on safety grounds. The total settlement of US$2.3 billion, comprising a US$1.195 billion criminal fine, then the largest ever imposed in the United States, and US$1 billion in civil payments, also covered Geodon, Zyvox and Lyrica. Because a felony conviction would have excluded Pfizer from Medicare and Medicaid, ending its American business, the plea was entered by a subsidiary created for the purpose, an arrangement critics described as demonstrating that a company of sufficient size cannot be meaningfully prosecuted.

Rapamune, 2013 and 2014. Wyeth, acquired by Pfizer, had promoted the immunosuppressant for transplant types for which it was not approved. Pfizer paid US$491 million.

Other matters

Trovafloxacin in Nigeria. In 1996, during a meningitis epidemic in Kano, Pfizer conducted a trial of the experimental antibiotic trovafloxacin on approximately 200 children. Eleven died and others suffered disability; the families alleged that consent had not been obtained and that the approval letter presented to authorities had been backdated. Pfizer maintained that the deaths were caused by meningitis and that the trial had been properly conducted. Litigation in Nigeria and the United States continued for more than a decade and was settled in 2011, with compensation paid through a trust fund and a scheme requiring DNA verification of participation.

Shiley heart valves. Pfizer's Shiley subsidiary made the Bjork-Shiley convexo-concave valve, in which a welded strut could fracture, causing sudden and usually fatal failure. Several hundred fractures occurred. The company settled for approximately US$200 million in 1994 and faced allegations that it had known of the defect and of manufacturing problems before withdrawing the valve.

Quigley and asbestos. The Quigley Company, a Pfizer subsidiary from 1968, made products containing asbestos. Pfizer eventually resolved the resulting claims through a settlement of approximately US$964 million in 2013 following protracted bankruptcy proceedings.

Whistleblowers. Peter Rost, a Pfizer vice president who publicly advocated drug reimportation and raised concerns about off-label marketing of a growth hormone, was dismissed in 2005 and wrote an account of the experience. Other employees have brought retaliation claims, including a 2010 case concerning a scientist who alleged exposure to an engineered virus and dismissal after litigating.

Pricing. The British Competition and Markets Authority fined Pfizer and the distributor Flynn Pharma for raising the price of phenytoin sodium capsules by up to 2,600 per cent after deliberately de-branding the medicine to remove it from price regulation. The original 2016 decision was appealed and remitted, and a revised penalty of approximately £63 million against Pfizer was imposed in 2022 and upheld in 2024.

mRNA patents. Moderna sued Pfizer and BioNTech in August 2022 alleging infringement of patents covering chemical modifications to mRNA and lipid nanoparticle formulation. In May 2024 the European Patent Office upheld the validity of one of the asserted patents. Litigation continues in several jurisdictions, with parallel claims from the University of Pennsylvania, Arbutus, GSK and CureVac, and the aggregate exposure is substantial.

COVID-19 vaccine criticism

Criticism of Pfizer's pandemic conduct falls into distinct categories and it is worth separating them.

Contracts and pricing. Advance purchase agreements with governments were negotiated confidentially, and versions obtained through litigation and leaks showed terms favourable to the company, including indemnities against liability, requirements that governments waive sovereign immunity in some cases, and confidentiality obligations. Prices per dose varied considerably between purchasers, and rose substantially after the acute phase. The European Commission's negotiations, including text messages between Bourla and the Commission president Ursula von der Leyen that the Commission was unable to produce in response to transparency requests, became the subject of an adverse finding by the European Ombudsman and of a ruling by the General Court in 2025 that the refusal was improper.

Equity of supply. Pfizer supplied the great majority of its early output to high-income countries and declined to license its technology through the World Health Organization's technology access pool, on the stated grounds that the manufacturing could not be transferred quickly and that quality could not be assured. Critics including Médecins Sans Frontières and the People's Vaccine Alliance argued that this delayed supply to lower-income countries by a year or more.

Safety and misinformation. The vaccine has been the subject of an enormous volume of false claims, and separating those from the real and documented adverse effects, principally myocarditis in young men and anaphylaxis at very low rates, has been made harder by both the volume of misinformation and by the reluctance of some public health authorities to discuss the genuine effects promptly. A statement by a Pfizer executive to a European Parliament committee in October 2022, that the vaccine had not been tested for prevention of transmission before launch, was accurate, was consistent with the published trial protocol, which measured symptomatic disease, and was widely presented as an admission of concealment.

Trial conduct. A BMJ report in November 2021 described data integrity problems at Ventavia, a contract research organisation running three of the trial's 153 sites, based on a former employee's account. Pfizer and the FDA said the issues did not affect the trial's conclusions.

Science and notable discoveries

Terramycin and the antibiotic era

Terramycin (oxytetracycline), isolated in 1949 from a soil actinomycete by a team under Alexander Finlay, was found through a screening programme in which Pfizer collected and tested soil samples from around the world, an approach that produced most of the antibiotics discovered in the 1940s and 1950s. Robert Woodward, later a Nobel laureate, determined its structure in collaboration with Pfizer, one of the earlier examples of an industrial and academic partnership on a chemical problem of that difficulty.

The launch in 1950 was accompanied by Pfizer's first sales force and its first consumer-facing advertising, and it established that a manufacturer could become a research and marketing company.

Sildenafil

Sildenafil was synthesised at Sandwich in 1989 as part of a programme on phosphodiesterase type 5, an enzyme that degrades cyclic GMP, the signalling molecule that causes smooth muscle to relax. Inhibiting it was expected to dilate coronary vessels and relieve angina.

Trials in angina were unimpressive. Participants reported penile erections as an adverse effect and were reluctant to return unused tablets. The team, led by Ian Osterloh, Peter Ellis, Nicholas Terrett and others, redirected the programme, and trials in erectile dysfunction produced clear results.

The scientific significance is that the mechanism was well understood before the application was identified, and that erectile dysfunction had previously been treated as psychological in the great majority of cases; the effectiveness of a drug acting on vascular smooth muscle established that it is usually a vascular condition, which changed its clinical framing.

The commercial significance was larger still. Viagra created a category, was prescribed at a volume nobody had forecast, and made the condition discussable in a way it had not been. Sildenafil is also approved, as Revatio, for pulmonary arterial hypertension, the indication closest to its original purpose.

Conjugate vaccine technology

Prevnar's underlying technology addresses a specific immunological problem. The capsule of Streptococcus pneumoniae is made of polysaccharide, and infants' immune systems respond poorly to polysaccharides because the response does not involve T cells and therefore produces no lasting memory. Chemically linking the polysaccharide to a carrier protein converts it into an antigen the T cell system recognises, producing a durable response in children under two, who are the population at greatest risk.

The approach, developed for Haemophilus influenzae type b in the 1980s and extended to pneumococcus by Wyeth, has been among the more consequential vaccine advances of the modern era. Invasive pneumococcal disease in young children fell very sharply in countries that introduced it, and herd effects reduced disease in adults who were never vaccinated.

The complication, which drives the succession of products, is serotype replacement: vaccinating against thirteen serotypes reduces those and allows others to fill the ecological space, requiring broader formulations. Prevnar 20 addresses twenty, and Merck's competing product addresses a different selection.

Messenger RNA

The Comirnaty platform delivers a synthetic messenger RNA encoding the SARS-CoV-2 spike protein inside a lipid nanoparticle. Cells take up the particle, translate the RNA into the protein, and the immune system responds to it.

Two problems had prevented this working for decades, and both were solved outside Pfizer. Unmodified RNA provokes a strong innate immune reaction that destroys it and causes inflammation; Katalin Karikó and Drew Weissman showed in 2005 that substituting pseudouridine for uridine largely eliminates this, work for which they received the 2023 Nobel Prize in Physiology or Medicine. And naked RNA does not enter cells; the lipid nanoparticle formulations that solve this were developed over twenty years principally at the University of British Columbia and at companies including Arbutus.

Pfizer's contribution was development, trial execution at extraordinary speed and scale, regulatory management across dozens of jurisdictions, and manufacture. This division of credit is the reason the patent litigation is complex and the reason critics of the company's pricing emphasise the public origins of the science.

The platform's wider promise, that a vaccine or therapeutic can be redesigned by changing a sequence rather than by redesigning a process, remains substantially unrealised outside COVID-19, with trials proceeding in influenza, respiratory syncytial virus and individualised cancer vaccines.

Antibody-drug conjugates

The Seagen portfolio rests on a modality whose principle is simple and whose execution took thirty years.

Cytotoxic chemotherapy kills dividing cells and cannot distinguish a tumour from bone marrow or intestinal lining, which is why its side effects take the form they do. An antibody-drug conjugate attaches a very potent cytotoxin to an antibody that binds a protein expressed preferentially on tumour cells, so that the toxin is delivered where it is wanted.

The difficulties are in the linker, which must hold the payload in circulation and release it inside the cell, in the drug-to-antibody ratio, and in the fact that no target is expressed exclusively on tumours, so that the toxicity profile follows the target's distribution. Adcetris, approved in 2011 for Hodgkin lymphoma, was among the first to work, and Padcev, in advanced urothelial cancer, produced survival results that changed practice.

The modality is now among the most contested in oncology, with Daiichi Sankyo and AstraZeneca's Enhertu the commercial leader, and it is the principal reason Pfizer paid US$43 billion for Seagen.

The pharmaceutical business model

Pfizer's behaviour, including the parts that attract criticism, follows from an economic structure worth setting out because it is not obvious.

A new medicine costs a very large and much-disputed sum to develop, with estimates ranging from several hundred million to more than two billion dollars depending on whether the cost of failures and the cost of capital are included. The great majority of candidates fail: roughly nine of every ten that enter human trials never reach approval, and the failures are expensive because the most costly trials come last.

The successful medicine is then protected by patents lasting twenty years from filing, of which perhaps eight to twelve remain by the time of approval, and by regulatory exclusivities. During that period the marginal cost of manufacture is typically a small fraction of the price, so revenue is very largely profit. At expiry, generic competitors enter and the price falls by 80 to 95 per cent within a year or two.

Three consequences follow.

First, the entire return on a research programme must be earned in a short window, which creates enormous pressure to maximise sales during it. Promotion to physicians, direct-to-consumer advertising, which is permitted only in the United States and New Zealand, and the pursuit of additional indications are all responses to that pressure, and off-label promotion is what happens when the pressure exceeds the constraint.

Second, the patent cliff is a recurring structural crisis rather than an event. Pfizer has faced three: Lipitor in 2011, which cost roughly US$10 billion of annual revenue; the post-pandemic decline; and the sequence beginning in the late 2020s as Eliquis, Ibrance and others expire. The response is always the same, acquisition, because buying a company with an approved medicine converts capital into revenue faster than research can.

Third, prices are set by what health systems will pay rather than by cost, which means they vary enormously between countries. American prices are typically several times European ones for the same product, because European systems negotiate as monopsonists and the United States until recently did not, and the industry's position is that American prices fund the research from which everyone benefits. The counter-position is that this is an argument for other countries paying more rather than a justification of the American level, and the Inflation Reduction Act of 2022, which permits Medicare to negotiate on selected medicines, is the first substantial American departure from the previous arrangement.

Therapeutic areas

Oncology is Pfizer's largest research commitment and the area in which the Seagen acquisition was made. The portfolio covers small molecules including the CDK4/6 inhibitor Ibrance and the androgen receptor inhibitor Xtandi, antibody-drug conjugates from Seagen including Padcev and Adcetris, and biologics. The modality that has changed most is the antibody-drug conjugate, which addresses the central problem of chemotherapy, that the agents are toxic to dividing cells generally, by delivering the toxin to cells carrying a specific surface marker.

Vaccines is a business Pfizer built principally through the Wyeth acquisition and then through the pandemic. Prevnar's conjugate technology, which links a polysaccharide from the bacterial capsule to a carrier protein so that infants' immune systems respond to it, is among the more important vaccine advances of the past forty years. Abrysvo addresses respiratory syncytial virus, a pathogen that causes a very large burden of infant hospitalisation and that had defeated vaccine development for six decades after a 1960s trial produced enhanced disease. Comirnaty established messenger RNA as a platform. A Lyme disease vaccine, developed with Valneva, completed its primary series in 2024 and would be the first available for humans since an earlier product was withdrawn in 2002 amid litigation and public concern.

Inflammation and immunology covers the JAK inhibitors Xeljanz and Cibinqo and a pipeline in inflammatory bowel disease, including etrasimod acquired with Arena Pharmaceuticals in 2022.

Internal medicine includes the cardiovascular and metabolic portfolio, Vyndaqel in amyloid cardiomyopathy, and, since Metsera, obesity.

Rare disease covers haemophilia gene therapies, including products that deliver a functional copy of a clotting factor gene, an area in which Pfizer has invested heavily and where commercial results across the industry have so far been disappointing relative to the scientific achievement.

Manufacturing and supply

Pfizer operates approximately 40 manufacturing sites worldwide and is among the largest producers of sterile injectable medicines, a category that includes most of what a hospital uses and that has very thin margins and chronic shortages.

Significant sites include Kalamazoo, Michigan, which produced much of the COVID-19 vaccine's American supply; Puurs in Belgium, the principal European vaccine site; Rocky Mount, North Carolina, which produces a substantial share of American hospital injectables and which was severely damaged by a tornado on 19 July 2023, causing national shortages that persisted for months; Grange Castle and Ringaskiddy in Ireland; Sanford, North Carolina, for gene therapy; and sites in Germany, Italy, China, India and Singapore.

The Rocky Mount episode illustrated a structural vulnerability that regulators and hospital systems had identified before it occurred. Sterile injectable production has consolidated into a small number of plants because the margins do not support redundancy, so that damage to one facility can remove a substantial share of national supply of medicines for which there is no substitute.

The October 2025 commitment of US$70 billion to American manufacturing, made in exchange for tariff relief, is directed partly at this and partly at the political demand that medicine production return to the United States.

Competition

Pfizer competes across therapeutic areas rather than as a whole, and its position differs sharply by area.

In vaccines it competes with Merck & Co., GSK, Sanofi and Moderna. Merck's V116 competes directly with Prevnar in adults, and GSK's Arexvy competes with Abrysvo.

In oncology the field is crowded, with Merck & Co.'s Keytruda the largest-selling medicine in the world, Bristol Myers Squibb, AstraZeneca, Roche, Johnson & Johnson and Daiichi Sankyo, whose antibody-drug conjugate partnership with AstraZeneca has been the most successful in that modality.

In obesity, the category that will shape the industry's next decade, Novo Nordisk and Eli Lilly hold a lead measured in years, and the contest among followers including Pfizer, AstraZeneca, Roche, Amgen and Chinese developers concerns oral formulations, tolerability and muscle preservation.

In immunology AbbVie, Johnson & Johnson, Eli Lilly and Sanofi hold strong positions.

Across all areas the competitive dynamic is increasingly determined by acquisition of biotechnology companies rather than by internal research, and the large companies compete for the same assets, which is why prices paid have risen and why the Metsera contest in 2025 became public.

Timeline

1849 Charles Pfizer and Charles Erhart found the company in Brooklyn.
1862 Production expands supplying the Union Army.
1919 Citric acid is produced by fermentation, making Pfizer the world's largest supplier.
1944 Deep-tank fermentation produces most of the penicillin used at the Normandy landings.
1950 Terramycin is launched, the first medicine sold under Pfizer's own name.
1980 Feldene becomes one of the first medicines to exceed US$1 billion in annual sales.
1991 Zoloft is approved.
1998 Viagra is approved in March.
2000 Warner-Lambert is acquired for approximately US$90 billion, bringing Lipitor.
2003 Pharmacia is acquired for approximately US$60 billion.
2004 Settles the gabapentin off-label promotion case for US$430 million.
2009 Wyeth is acquired for approximately US$68 billion; the Bextra settlement of US$2.3 billion is the largest healthcare fraud settlement to that date.
2011 Lipitor loses patent protection; the Sandwich research site is substantially reduced.
2013 Zoetis is separated.
2016 The proposed Allergan merger is abandoned after United States Treasury rule changes.
2019 Albert Bourla becomes chief executive; the consumer health joint venture with GSK is formed.
2020 The BioNTech collaboration produces the first Western COVID-19 vaccine, authorised in the United Kingdom on 2 December.
2021 Revenue approaches US$81 billion; Paxlovid is authorised in December.
2022 Revenue exceeds US$100 billion; Haleon is demerged; Moderna sues over mRNA patents.
2023 Revenue falls by more than 40 per cent; Seagen is acquired for approximately US$43 billion; the Rocky Mount plant is damaged by a tornado.
2025 The remaining Haleon stake is sold for US$3.24 billion; danuglipron is abandoned in April; an agreement with the Trump administration on prices and tariffs is reached in October; Metsera is acquired in November.

Corporate affairs

Leadership

Albert Bourla has been chief executive since January 2019 and chairman since 2020. Born in Thessaloniki to a Jewish family that survived the Holocaust, he trained as a veterinarian with a doctorate in reproductive biotechnology, joined Pfizer's animal health division in Greece in 1993, and rose through the animal health and vaccines businesses. His account of the vaccine programme, Moonshot, was published in 2022.

His predecessors include Ian Read, chief executive from 2010 to 2018, who conducted the divestments and the attempted inversions; Jeffrey Kindler, 2006 to 2010, a lawyer whose tenure ended abruptly; Hank McKinnell, 2001 to 2006, under whom the Pharmacia acquisition was made and whose pension arrangements became a governance controversy; and William Steere, whose tenure produced Lipitor, Viagra and the Warner-Lambert acquisition.

The headquarters moved in 2022 from 235 East 42nd Street, which the company had occupied since 1961, to The Spiral at Hudson Yards.

Finances

Revenue was approximately US$81 billion in 2021 and US$100 billion in 2022 at the peak of the pandemic products, fell to approximately US$58 billion in 2023, and was approximately US$62.6 billion in 2025.

The company's central financial problem is the patent cliff approaching in the second half of the decade, when Eliquis, Ibrance, Xeljanz, Xtandi and Vyndaqel lose exclusivity in sequence, representing a very large share of current revenue. The Seagen acquisition, the pipeline in oncology and obesity, and the cost reduction programme are all directed at it.

Pfizer pays a substantial dividend, which the board has treated as a commitment and which constrains its capacity for further large acquisitions, and it carried significant debt after the Seagen purchase.

Lobbying and political activity

Pfizer is consistently among the largest corporate lobbying spenders in the United States, typically in the range of US$10 million to US$14 million a year, and is a major funder of the industry association PhRMA.

Its political priorities have included opposing direct government negotiation of Medicare drug prices, which was nonetheless introduced by the Inflation Reduction Act of 2022 and which began affecting selected medicines including Eliquis from 2026; opposing drug importation; defending patent terms and regulatory exclusivities; and, more recently, negotiating over tariffs, which produced the October 2025 agreement.

The company has faced criticism for the volume of payments it makes to physicians and teaching hospitals, disclosed under the Physician Payments Sunshine Act, and for funding patient advocacy organisations that then lobby on matters affecting its products.

Environment

Pfizer has committed to net zero by 2040 and to reducing operational emissions substantially by 2030, and reports progress against those targets.

Historical liabilities are substantial, including contamination at legacy manufacturing and chemical sites and the Quigley asbestos matter. Pharmaceutical manufacturing effluent, and the presence of active ingredients and antibiotic residues in waterways near production sites, is an industry-wide problem in which Pfizer's supply chain in India and China has been examined.

The environmental footprint of vaccine distribution, in particular the dry ice and single-use thermal shipping required for the ultra-cold chain, drew comment during the pandemic and has been reduced as formulations tolerant of ordinary refrigeration were approved.

Philanthropy and access

The Pfizer Foundation funds health system strengthening and non-communicable disease programmes.

The company's most substantial access commitment is An Accord for a Healthier World, announced in 2022, under which Pfizer offers its full portfolio of patented medicines and vaccines on a not-for-profit basis to 45 lower-income countries. Assessments have been mixed: the commitment is broader than any competitor's, and uptake has been limited by the capacity of health systems to register, procure and distribute the products, which critics say the company knew and which the company says it is working to address through regulatory support.

Pfizer has also participated in donation programmes including the International Trachoma Initiative, to which it has supplied azithromycin for more than two decades, a programme generally regarded as among the more effective corporate donation schemes in global health.

Acquisitions

Pfizer's growth since 1990 has been driven as much by acquisition as by research, and the list is long enough to be worth setting out.

Major transactions: Warner-Lambert, 2000, approximately US$90 billion, bringing Lipitor, Listerine, Schick and the Parke-Davis research operation; Pharmacia, 2003, approximately US$60 billion, bringing Celebrex, Xalatan, Detrol, Depo-Provera and the animal health business; Wyeth, 2009, approximately US$68 billion, bringing Prevnar, Enbrel outside North America, Effexor and biologics manufacturing; King Pharmaceuticals, 2010, approximately US$3.6 billion; Hospira, 2015, approximately US$17 billion, bringing generic injectables and biosimilars; Medivation, 2016, approximately US$14 billion, bringing Xtandi; Anacor, 2016, approximately US$5.2 billion; Array BioPharma, 2019, approximately US$11.4 billion, bringing Braftovi and Mektovi; Arena Pharmaceuticals, 2022, approximately US$6.7 billion, bringing etrasimod; Biohaven, 2022, approximately US$11.6 billion, bringing Nurtec; Global Blood Therapeutics, 2022, approximately US$5.4 billion, bringing Oxbryta for sickle cell disease, subsequently withdrawn in 2024 after post-marketing data showed increased mortality; Seagen, 2023, approximately US$43 billion, bringing four approved antibody-drug conjugates and a large pipeline; and Metsera, 2025, potentially exceeding US$10 billion, bringing obesity candidates.

Failed transactions: the 2014 approach to AstraZeneca at approximately US$118 billion, rejected; the 2015 proposed merger with Allergan at approximately US$160 billion, abandoned in April 2016 after United States Treasury rules were changed to prevent the tax inversion.

Divestments: Zoetis, animal health, separated in 2013; the infant nutrition business sold to Nestlé in 2012 for approximately US$11.85 billion; Capsugel sold in 2011; the consumer health business contributed to the GSK joint venture in 2019 and demerged as Haleon in 2022, with the residual stake sold in March 2025 for US$3.24 billion; Upjohn, the off-patent portfolio, spun off in November 2020 and merged with Mylan to form Viatris; and the Hospira Infusion Systems business sold to ICU Medical in 2017.

The pattern is consistent: acquire innovative medicines, divest everything that is not an innovative medicine. The strategic reasoning is that a research-based company has no advantage in consumer goods, generics, nutrition or animal health, and that the capital is better applied where patents create pricing power.

The record of the individual transactions is mixed. Warner-Lambert was exceptionally good. Wyeth brought Prevnar, which has justified it. Pharmacia is generally regarded as having delivered less than it cost. Hospira was a strategic move into biosimilars that Pfizer subsequently de-emphasised. Seagen is the bet on which the next decade depends and it is too early to judge.

Global operations

Pfizer operates in most countries and organises commercially around the United States, developed Europe, emerging markets and a small number of large individual markets.

The United States produces roughly half of revenue and considerably more than half of profit, because American prices are materially higher than elsewhere for the same products. This concentration is the company's principal political exposure, and the Inflation Reduction Act's negotiation provisions, which began affecting Eliquis among the first selected medicines, together with the October 2025 tariff agreement, are both consequences of it.

Europe is a large volume market at lower prices, negotiated country by country through health technology assessment bodies including NICE in England, IQWiG and the G-BA in Germany and the Haute Autorité de Santé in France, each of which assesses whether a medicine's benefit justifies its price. Pfizer maintains substantial manufacturing in Belgium, Ireland and Italy and research at Sandwich, much reduced since 2011.

China has been a significant growth market and a difficult one, subject to volume-based procurement tendering that has cut prices for off-patent medicines very sharply, and to a domestic industry that has become a serious competitor in several categories.

Japan is the second largest single market by value and operates on a biennial price revision system that reduces prices over a product's life.

Emerging markets generally involve lower prices, tiered pricing arrangements and, since 2022, the Accord for a Healthier World for the lowest-income countries.

Workforce and culture

Pfizer employs approximately 81,000 people, a figure reduced substantially by the cost programme that followed the pandemic decline.

The company received a score of 100 per cent on the Human Rights Campaign's Corporate Equality Index in 2025 and has ranked highly on the Hispanic Association on Corporate Responsibility's inclusion index, and has been named among the better places to work in several national surveys.

Its research workforce is concentrated in Connecticut, Massachusetts, California and New York in the United States and in Kent, Belgium and Ireland in Europe, and its commercial organisation is very large, reflecting an industry in which the sales force calling on physicians remains a principal channel despite decades of predictions that digital communication would replace it.

The shift toward digital engagement accelerated during the pandemic, when representatives could not visit physicians, and the omnichannel approach the company described in January 2024 reflects a permanent change in the proportion of contact conducted remotely.

Reception

Public perception of Pfizer changed more sharply between 2020 and 2023 than that of almost any company.

Before the pandemic it was a large, unglamorous pharmaceutical company principally known for Viagra and for legal settlements. During 2020 and 2021 it was widely regarded as having done something extraordinary, and Bourla was among the more admired executives in the world. From 2022 onward the company became a focus of organised hostility from vaccine opponents, and simultaneously of criticism from global health advocates over pricing and supply, so that it now occupies the unusual position of being attacked from directions that have nothing in common.

The professional assessment is more stable. Within the industry Pfizer is regarded as an exceptional manufacturer and an effective acquirer, with a research organisation that has produced less than its size implies. Among health economists the company is a standard case study in the tension between the returns necessary to fund development and the prices that health systems can bear. Among regulators and prosecutors its compliance record is among the worst of any large company, a judgement supported by the sequence of settlements rather than by any single one.

The most consequential open question is whether the pandemic was a transformation or an interruption. Pfizer emerged with approximately US$40 billion of additional cash and used it on Seagen; it has since faced the same patent cliff it would have faced anyway, with a weaker pipeline in the categories that matter most. On that reading the vaccine bought the company a very large acquisition and did not change its trajectory. The alternative reading is that mRNA is a platform whose applications in oncology and in rare disease have not yet been realised, and that Pfizer's position in it is worth more than its current products. Both readings are available and the evidence to choose between them does not yet exist.

Assessment

Pfizer's history divides into two kinds of achievement and one persistent failure.

The achievements of manufacturing are the less celebrated and arguably the greater. Deep-tank fermentation in 1919, penicillin at scale in 1943 and three billion doses of an entirely novel vaccine in 2021 are each instances of the same capability: the ability to make something in quantities nobody had made before, under time pressure, at acceptable quality. This is not what pharmaceutical companies are usually praised or criticised for, and it is what Pfizer has done better than anyone for a century.

The achievements of discovery are more uneven than the company's size suggests. Viagra and Prevnar are Pfizer's; Lipitor, Eliquis, Xtandi, Prevnar's original technology, Comirnaty and the Seagen portfolio came from elsewhere and were acquired or partnered. This is not a criticism in itself, since identifying what to buy is a skill and Pfizer has exercised it well, notably with Warner-Lambert and with BioNTech. It does mean that the company's position depends on capital allocation more than on its laboratories, and its record in obesity, where it failed twice internally and then paid more than US$10 billion for a position, is the recent illustration.

The failure is the commercial conduct. A company that has pleaded guilty to a felony for promoting a medicine the regulator refused to approve, and that has settled comparable allegations three other times, has demonstrated something about its incentives rather than about particular employees. The penalties, though very large in absolute terms, have been small relative to the revenue the conduct generated, which is the reason it recurred, and the use of a subsidiary to absorb the 2009 conviction so that the parent could continue to sell to Medicare is the clearest available evidence that the deterrent does not function as intended.

The pandemic made all three visible at once: an extraordinary manufacturing feat, built on a platform the company did not invent and on science it did not fund, distributed under confidential contracts on terms governments could not discuss and largely to countries that could pay.